AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02201511
Drug: 2 x 15 mg PF-06412562 MR tablets_Fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
Trial: NCT02201511
Drug: 10 mg PF-06412562 IR tablets
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
Trial: NCT00423696
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00423696
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00423696
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04290390
Drug: Segesterone Acetate and Ethinyl Estradiol
RxNorm normalized name: ETHINYL ESTRADIOL/SEGESTERONE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive Vaginal System
Trial: NCT01794533
Drug: Lidocaine with Epinephrine+ Normal saline
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
Trial: NCT01794533
Drug: Lidocaine with Epinephrine + fentanyl
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
Trial: NCT00665717
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg tablet; QD; 4 days
Trial: NCT00665717
Drug: Pravastatin and raltegravir
RxNorm normalized name: lamivudine and raltegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
Trial: NCT04087707
Drug: Step 1: TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
Trial: NCT04087707
Drug: Step 2: TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elderly participants will receive 20 mg of TS-142 once daily for 7 consective days
Trial: NCT04087707
Drug: Step 2: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elderly participants will receive placebo once daily for 7 consective days
Trial: NCT04449471
Drug: Naproxen tablet
RxNorm normalized name: Naproxen Tablets
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
Trial: NCT04573153
Drug: Hydroxychloroquine + Sorbitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
Trial: NCT00667498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.~The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia.
Trial: NCT05155072
Drug: DW1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DW1903
Trial: NCT05155072
Drug: DW1903-R2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DW1903-R2
Trial: NCT03533582
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03533582
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01358708
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
Trial: NCT03978689
Drug: CUE-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
Trial: NCT00540098
Drug: Placebo + aerobic exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill once daily + regular aerobic exercise
Trial: NCT00540098
Drug: Placebo + relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pill once daily + regular relaxation training
Trial: NCT01377285
Drug: ARB
RxNorm normalized name: Arbli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan
Trial: NCT03119701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilisate for solution for injection as placebo.
Trial: NCT00051636
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
Trial: NCT00051636
Drug: Placebo to Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mL of sterile water one dose intravenous infusion.
Trial: NCT05594316
Drug: Trichloroacetic acid
RxNorm normalized name: Trichloroacetic Acid
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5. Patients will be subjected to 3 session of trichloroacetic acid 35% one month apart.
Trial: NCT03684980
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (Cohort A) will receive MTX 3 g/m2 or (Cohort B) will receive MTX 8 g/m\^2 (Cohort E) will receive MTX ≤ 3.5 g/ m2
Trial: NCT03684980
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will also receive standard of care leucovorin rescue starting at least 24 hours after MTX and 2 hours after Voraxaze. Cycles will be 14 days long.
Trial: NCT02672917
Drug: modified FOLFIRINOX (mFOLFIRINOX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01146431
Drug: Inhaled anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
Trial: NCT01146431
Drug: Inhaled anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
Trial: NCT04536467
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard chemotherapy
Trial: NCT00177099
Drug: FK506, GP11046, GP11511
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04427709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular placebo injection
Trial: NCT03932435
Drug: Fisrt period TWLO_C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)
Trial: NCT03932435
Drug: Fisrt period TWLO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First Period: Single oral administration of 1 tablet of Twolion Tab(Bepotastine Besilate 10mg)
Trial: NCT03932435
Drug: Second period TWLO_C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second Period: Single oral administration of 1 tablet of Dong-a Bepotastine Besilate Tab(Bepotastine Besilate 10mg)
Trial: NCT01190826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once by inhalation
Trial: NCT00725725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
Trial: NCT01672307
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is applied twice daily to the other eyebrow.
Trial: NCT01829295
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
Trial: NCT04571515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT04721912
Drug: Probiotic dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GBS positive patients, at ≥ 36 weeks gestation, will begin taking oral Florajen Digestion probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth.
Trial: NCT05154201
Drug: ORIN1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
Trial: NCT01086410
Drug: Placebo Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
Trial: NCT01086410
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule taken each day on the last 7 days of the study
Trial: NCT01086410
Drug: Prednisolone Oral Capsule
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
Trial: NCT03749525
Drug: shenfu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
Trial: NCT02105766
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immunosuppressant
Trial: NCT04030039
Drug: nucleoside analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chronic hepatitis B patients with interferon therapy
Trial: NCT01971502
Drug: Placebo to BI 1060469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single rising doses
Trial: NCT00515255
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules
Trial: NCT03034460
Drug: CD5024 1% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 µL on half-face, five days a week during 6 weeks
Trial: NCT03034460
Drug: CD0271/CD1579 gel placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 µL on half-face, five days a week during 6 weeks
Trial: NCT03701399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04556838
Drug: VVN001 Ophthalmic Solution 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVN001 Ophthalmic Solution 1%
Trial: NCT04556838
Drug: VVN001 Ophthalmic Solution 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVN001 Ophthalmic Solution 5%
Trial: NCT04556838
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVN001 Ophthalmic Solution Vehicle
Trial: NCT00995930
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACZ885 150 mg was administered subcutaneously once a month for 12 months.
Trial: NCT03516838
Drug: ACTIVA™ BioACTIVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
Trial: NCT03516838
Drug: Compomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
Trial: NCT03642665
Drug: Natural cycle
RxNorm normalized name: Natural Cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no medication
Trial: NCT03505320
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin will be administered as a 2-hour IV infusion.
Trial: NCT03505320
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
Trial: NCT03959085
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03959085
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03959085
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV
Trial: NCT03959085
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03959085
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT or IV
Trial: NCT03959085
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO or IV
Trial: NCT01799213
Drug: Meloxicam 15 mg po QD
RxNorm normalized name: meloxicam 15 MG
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible subjects will be take Meloxicam 15 mg po QD
Trial: NCT00554788
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04437511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03355469
Drug: Low Intensity Exercise + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.
Trial: NCT03355469
Drug: High Intensity Exercise + Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.
Trial: NCT01585831
Drug: Testosterone gel 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
Trial: NCT01585831
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
Trial: NCT04768023
Drug: Juvit D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.
Trial: NCT04768023
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching amount of vegetable oil to the vitamin D3.
Trial: NCT00259779
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01698281
Drug: AEZS-108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity.
Trial: NCT00857532
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
Trial: NCT04367883
Drug: ACEI
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention is performed. We propose an observational study.
Trial: NCT04367883
Drug: ARB
RxNorm normalized name: Arbli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention is performed. We propose an observational study.
Trial: NCT01205438
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Trial: NCT01205438
Drug: Placebo every 2 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
Trial: NCT01205438
Drug: Placebo every 4 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection for 52 weeks.
Trial: NCT00346099
Drug: Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00346099
Drug: Panitumumab with capecitabine and radiation
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT05053477
Drug: mehylprednisolone injection
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (40 mg)
Trial: NCT03632109
Drug: gentamicin 360mg IM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360mg IM of gentamicin
Trial: NCT00828373
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
Trial: NCT02623426
Drug: Intravitreal Methotrexate 400 µg
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
Trial: NCT03490162
Drug: DM1157
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DM1157 is a novel anti-malarial drug that is derived from chloroquine. DM1157 maintains the efficacy of chloroquine and has molecular features that overcome resistance to chloroquine.
Trial: NCT02630199
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
Trial: NCT01233869
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral dose of placebo
Trial: NCT01245634
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv infusion every 4 weeks, 32 weeks
Trial: NCT01245634
Drug: RO4905417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg iv infusion every 4 weeks, 32 weeks
Trial: NCT00650065
Drug: Zyrtec® Tablets 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg, single dose fasting
Trial: NCT04123483
Drug: EnBrace HR Softgel
RxNorm normalized name: EnBrace HR Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 week study
Trial: NCT02953132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02676856
Drug: Conditioning for CR group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
Trial: NCT02676856
Drug: Conditioning for Non-CR group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
Trial: NCT05829707
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A group of patients with breast cancer who were randomized to the diclofenac group by drawing random numbers was given 2 x 75 mg of drug IV on the first PO day and then 3 x 50 mg tablets orally for postoperative analgesia.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4